Literature DB >> 9555016

Midkine exists in astrocytes in the early stage of cerebral infarction.

S Wang1, Y Yoshida, M Goto, T Moritoyo, J Tsutsui, S Izumo, E Sato, T Muramatsu, M Osame.   

Abstract

Midkine (MK), a heparin-binding neurotrophic factor, is expressed in the early stage of experimental cerebral infarction in the zone surrounding the infarct. Double immunostaining with anti-MK and anti-glial fibrillary acidic protein showed existence of MK in astrocytic cytoplasm on postoperative day 2. Immunoelectron microscopic analysis revealed the presence of MK in the swollen astrocytic processes on postoperative day 4.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9555016     DOI: 10.1016/s0165-3806(97)00213-7

Source DB:  PubMed          Journal:  Brain Res Dev Brain Res        ISSN: 0165-3806


  6 in total

Review 1.  Multiple system atrophy: cellular and molecular pathology.

Authors:  D J Burn; E Jaros
Journal:  Mol Pathol       Date:  2001-12

2.  The effects of early exercise on brain damage and recovery after focal cerebral infarction in rats.

Authors:  F Matsuda; H Sakakima; Y Yoshida
Journal:  Acta Physiol (Oxf)       Date:  2011-02       Impact factor: 6.311

Review 3.  Midkine: a promising molecule for drug development to treat diseases of the central nervous system.

Authors:  Takashi Muramatsu
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

4.  Correlation of elevated level of blood midkine with poor prognostic factors of human neuroblastomas.

Authors:  S Ikematsu; A Nakagawara; Y Nakamura; S Sakuma; K Wakai; T Muramatsu; K Kadomatsu
Journal:  Br J Cancer       Date:  2003-05-19       Impact factor: 7.640

Review 5.  Midkine in repair of the injured nervous system.

Authors:  Yoshihiro Yoshida; Harutoshi Sakakima; Fumiyo Matsuda; Masako Ikutomo
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

6.  Midkine: a novel prognostic biomarker for cancer.

Authors:  Hirofumi Jono; Yukio Ando
Journal:  Cancers (Basel)       Date:  2010-04-20       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.